This book encapsulates recent applications of CI methods in the field of computational oncology, especially cancer diagnosis, prognosis, and its optimized therapeutics. The cancer has been known as a heterogeneous disease categorized in several different subtypes. According to WHO’s recent report, cancer is a leading cause of death worldwide, accounting for over 10 million deaths in the year 2020. Therefore, its early diagnosis, prognosis, and classification to a subtype have become necessary as it facilitates the subsequent clinical management and therapeutics plan. Computational intelligence (CI) methods, including artificial neural networks (ANNs), fuzzy logic, evolutionary computations, various machine learning and deep learning, and nature-inspired algorithms, have been widely utilized in various aspects of oncology research, viz. diagnosis, prognosis, therapeutics, and optimized clinical management. Appreciable progress has been made toward the understanding the hallmarks of cancer development, progression, and its effective therapeutics. However, notwithstanding the extrinsic and intrinsic factors which lead to drastic increment in incidence cases, the detection, diagnosis, prognosis, and therapeutics remain an apex challenge for the medical fraternity. With the advent in CI-based approaches, including nature-inspired techniques, and availability of clinical data from various high-throughput experiments, medical consultants, researchers, and oncologists have seen a hope to devise and employ CI in various aspects of oncology. The main aim of the book is to occupy state-of-the-art applications of CI methods which have been derived from core computer sciences to back medical oncology. This edited book covers artificial neural networks, fuzzy logic and fuzzy inference systems, evolutionary algorithms, various nature-inspired algorithms, and hybrid intelligent systems which are widely appreciated for the diagnosis, prognosis, and optimization of therapeutics of various cancers. Besides, this book also covers multi-omics exploration, gene expression analysis, gene signature identification of cancers, genomic characterization of tumors, anti-cancer drug design and discovery, drug response prediction by means of CI, and applications of IoT, IoMT, and blockchain technology in cancer research.

This book describes both the technologies used in the discovery of melanoma biomarkers and the clinical application of these biomarkers for diagnosis and staging of disease, determination of prognosis, treatment planning, monitoring of response to therapy, identification of novel therapeutic targets and drug development. A broad range of biomarkers (DNA/chromosomal, mRNA, microRNA, mitochondrial DNA, epigenetic and protein) is outlined. As therapies for melanoma become increasingly more target specific, the identification, validation and use of biomarkers will invariably play a greater role in the management of patients with this disease. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma is an essential resource for oncologists, dermatologists, dermatopathologists, general pathologists with an interest in melanoma, and melanoma researchers.

In the last couple of decades, the study of the cancer genome and the progressive implementation of next-generation sequencing platforms have provided the Scientific and Oncology communities with a multitude of data, technologies, diagnostic, prognostic, and predictive tools that have been revolutionizing the way we can study, diagnose and treat cancer, including breast tumors. For example, genomic tests can now refine the prognosis of early-stage breast cancer patients beyond standard clinicopathological features and help guide escalated or de-escalated treatment choices. The identification of the molecular intrinsic subtypes might also be helpful in guiding treatment choices in advanced hormone receptor-positive disease. The identification of germline mutations in BRCA1 or BRCA2 has led to the development and introduction of PARP inhibitors for the treatment of advanced and early-stage breast cancer, along with personalized follow-up and prophylactic surgical procedures for patients with or without cancer, carrying such mutations.

This book is a continuance of the topic: “DAMPs in Human Diseases”, the basics of which were described in a first volume by the same author. This second volume presents our current understanding of the impact of sterile stress/injury-induced innate immune responses on the etiopathogenesis of human diseases by focusing on those diseases that are pathogenetically dominated by DAMPs, i.e., on polytrauma, various solid organ injuries (brain, lung, kidney, liver), atherosclerosis, and cerebro-cardiovascular diseases. Our growing understanding of the pathogenetic function of activating DAMPs and suppressive DAMPs (“SAMPs”) is used as a point of departure to explore how these molecules can be used as biomarkers to extend and improve current diagnostic and prognostic modalities. Moreover, this new knowledge about the pathogenetic function of DAMPs and SAMPs is taken as a sound and plausible reason for discussing their implications for present and future treatment of the diseases addressed here. In this context, the focus is on the potential of DAMPs as future therapeutic targets and SAMPs as future therapeutics, applied in strict compliance with safety precautions, as also recommended in this work. The book is intended for professionals from all medical and paramedical disciplines who are interested in applying innovative data from inflammation and immunity research to clinical practice. The readership will include practitioners and clinicians working in the broad field of acute and chronic inflammatory/fibrotic diseases, in particular, traumatologists and intensivists; neurologists and neurosurgeons; cardiologists and cardiac surgeons; pulmonologists and thoracic surgeons; vascular surgeons; nephrologists; gastroenterologists and hepatologists; and pharmacists. Also available: Damage-Associated Molecular Patterns in Human Diseases - Vol. 1: Injury-Induced Innate Immune Responses

First introduced to biomedical research in 1980, the term biomarker has taken on a life of its own in recent years and has come to mean a number of things. In biomedical science, biomarker has evolved to most commonly mean a characteristic that can be used either as a diagnostic or a prognostic, but most significantly as a screening indicator for p

Gleaning information from more than 100 experts in the field of cancer diagnosis, prognosis, and therapy worldwide, Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis determines the significance of clinical validation approaches for several markers. This book examines the use of noninvasive or minimally invasive molecular cancer markers that are under development or currently in use. It deals with a majority of commonly prevalent cancers and can help anyone working in the health-care industry to recommend or develop early diagnostics, at-risk tests, and prognostic biomarkers for various cancers. It explores the practice of determining biomarkers by their characteristics and relative methodologies, and presents the most recent data as well as a number of current and upcoming early diagnostic noninvasive molecular markers for many common cancers. It also considers the sensitivity and specificity of markers, biomarker market, test providers, and patent information. Approximately 30-35 Cancer Specific Noninvasive Molecular Diagnostic Markers in a Single Volume The book details the general and technical aspects of noninvasive cancer markers. It covers imaging, cutting-edge molecular technologies for biomarker development, and noninvasive or minimally invasive sources of molecular markers, as well as quality control and ethical issues in cancer biomarker discovery. It also provides a detailed account of brain, head and neck, and oral cancer markers, and provides information on a number of gastrointestinal cancers, lung cancer, and mesothelioma markers. Emphasizes the Importance of Volatile Markers in Early Cancer Diagnosis Presents noninvasive early molecular markers in urological cancers Describes gynecological and endocrine cancer markers Details noninvasive markers of breast, ovarian, cervical, and thyroid cancers Addresses hematological malignancies Contains information on noninvasive molecular markers in myelodysplastic syndromes, acute myeloid leukemia, Hodgkin’s lymphoma, and multiple myeloma Provides comprehensive information on diagnostic and prognostic biomarkers in cutaneous melanoma This text considers molecular technologies for biomarker development, noninvasive or minimally invasive sources of molecular markers, and quality control and ethical issues in cancer biomarker discovery.